Abstract
Mycophenolate mofetil (MMF) is an orally bioavailable prodrug of mycophenolic acid (MPA), a potent immunosuppressive agent. MPA acts by inhibiting inosine monophosphate dehydrogenase (IMPDH), which catalyzes the first step in de novo synthesis of guanine (Ransom, 1995). This process is critical to mitogen-stimulating lymphocytes, which gives rise to MPA’s therapeutic efficacy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Birkinshaw JH, Raistrick H, and Ross DJ. Studies in the Biochemistry of Microorganisms 86. The Molecular Constitution of Mycophenolic Acid, A Metabolic Product of Penicillium Brevi-Compactum Dierckx. Part 3. Further Observations on the Structural Formula for Mycophenolic Acid. Biochem J 1952; 50:630–634
Conaway CC, Tong C, and Williams GM. Evaluation of Morpholine, 3-Morpholinone, and N-Substituted Morpholines in the Rat Hepatocyte Primary Culture/DNA Repair Test. Mutat Res 1984; 136:153–157
Epinette WW, Parker CM, Jones EL, and Griest MC. Mycophenolic Acid for Psoriasis, A Review of Pharmacology, Long-Term Efficacy, and Safety. J Am Acad Dermatol 1987; 17:962–971
Fulton B and Markham A. Mycophenolate Mofetil: A Review of its Pharmacodynamic and Pharmacokinetic Properties and Clinical Efficacy in Renal Transplantation. Drugs 1996; 51: 278–298
Gosio B. Ricerche Batteriologiche e Chimiche Sulle Alterazoni del Mais. Riv Ig Pubblica 1896; 7:825–868
Hood KA and Zarembski DG. Mycophenolate Mofetil: A Unique Immunosuppressive Agent. Am J Health-Syst Pharm 1997; 54:285–294
Jones EL, Epinette WW, Hackney VC, Menendez L, and Frost P. Treatment of Psoriasis with Oral Mycophenolic Acid. J Invest Dermatol 1975; 65:537–542
Lee WA, Gu L, Miksztal AR, Chu N, Leung K, and Nelson PH. Bioavailability Improvement of Mycophenolic Acid Through Amino Ester Derivatization. Pharm Res 1990; 7:161–166
Marinari R, Fleischmajer R, Schragger AH, and Rosenthal AL. Mycophenolic Acid in the Treatment of Psoriasis. Arch Dermatol 1977; 113:930–932
Nelson PH, Gu CLL, Allison AC, Eugui EM, and Lee WA. Heterocyclic Aminoalkyl Esters of Mycophenolic Acid, Derivatives Thereof and Pharmaceutical Compositions. US Patent #4,727,069 (February 23) 1988
Ransom JT. Mechanism of Action of Mycophenolate Mofetil. Ther Drug Monit 1995; 17:681–684
Roche Laboratories. CellCept® Complete Product Information. 2003
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 American Association of Pharmaceutical Scientists
About this chapter
Cite this chapter
Marinaro, W.A. (2007). Case Study: Mycophenolate Mofetil. In: Stella, V.J., Borchardt, R.T., Hageman, M.J., Oliyai, R., Maag, H., Tilley, J.W. (eds) Prodrugs. Biotechnology: Pharmaceutical Aspects, vol V. Springer, New York, NY. https://doi.org/10.1007/978-0-387-49785-3_47
Download citation
DOI: https://doi.org/10.1007/978-0-387-49785-3_47
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-49782-2
Online ISBN: 978-0-387-49785-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)